HF
WINT

HRT Financial’s Windtree Therapeutics WINT Stock Holding History

HRT Financial’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-221
Closed -$3K – 3492
2024
Q4 		$3K Buy
+221
New +$7.01K ﹤0.01% 2335
2023
Q1 		– Sell
-1
Closed -$5K – 3276
2022
Q4 		$5K Buy
+1
New +$8.89K ﹤0.01% 2272
2021
Q2 		– Sell
-1
Closed -$57K – 3616
2021
Q1 		$57K Buy
+1
New +$216K ﹤0.01% 2531

Other funds holding WINT

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

HRT Financial's WINT Position: Q1 2025 in Review

HRT Financial sold out of Windtree Therapeutics (WINT) in Q1 2025, closing a stake of 221 shares — an estimated $3K sold.

HRT Financial first reported a position in WINT in Q1 2021 and held it in 3 quarters. The position peaked at $57K in Q1 2021. 5 funds tracked by Wall St. Rank hold WINT as of Q1 2025.

  • HRT Financial reported no remaining Windtree Therapeutics position as of Q1 2025 after selling out during the quarter.
  • HRT Financial sold 221 Windtree Therapeutics shares in Q1 2025, an estimated $3K.
  • HRT Financial first reported a position in Windtree Therapeutics in Q1 2021 and held it in 3 quarters.
  • HRT Financial's Windtree Therapeutics position peaked at $57K in Q1 2021.
  • 5 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q1 2025.

Based on HRT Financial's 13F filing for Q1 2025, filed 15 May 2025.